Breaking News, Financial News

WuXi PharmaTech

Lab and manufacturing revenues on the rise

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

WuXi PharmaTech 2Q10

2Q Revenues: $81 million (+21%)

2Q Earnings: $14 million (-6%)

YTD Revenues: $162 million (+28%)

YTD Earnings: $29 million (+11%)

Comments: Lab services in China brought in $53 million in 2Q10 revenues (+18%), while U.S. lab services were up 19% to $20 million. For 1H10, China lab services were $103 million (+19%) and U.S. lab revenues were $37 million (+17%). Manufacturing services, which are based in China were up 55% in 2Q10 to $8.5 million and up 175% for 1H10 to $22 million, driven by demand for clinical trial supplies.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters